Press Release – Jan. 27, 2012

University of Illinois, Urbana-Champaign Office of Technology Management:

Urbana, IL – Vanquish Oncology, Inc. is a drug development company focused on targeting molecular defects in specific cancer cells to create personalized oncology therapeutics for unmet or underserved cancer markets.

Vanquish Oncology focuses on small molecule compounds developed by Professor Paul Hergenrother of the Department of Chemistry at the University of Illinois at Urbana-Champaign which target cell apoptosis (cell death) across multiple tumor types. Pre-clinical data indicate that clinical candidates are well tolerated and efficacious in rodents and canines. Additionally, the compounds exhibit synergistic effects when used in combination with common front-line anti-cancer agents.

Read full press release